Promakhos Therapeutics Analysis: $125K Raised
What is Promakhos Therapeutics?
Promakhos Therapeutics is a Boston-based biotech startup founded in spring 2021. It develops medicines for inflammatory diseases by using patient-sample insights to address root causes, rather than broadly suppressing immunity. The company’s lead work is an oral Crohn’s disease candidate intended to restore intestinal innate immune function and wound healing.
Location
127 Western Ave, Boston, Massachusetts 02134, United States
Employees
1-10
Founded
2021
Revenue
<$5M
Product Features & Capabilities
- treatments for autoimmune diseases, therapies that restore immune system function, solutions for inflammatory disorders, focus on healing and controlling inflammation
How much Promakhos Therapeutics raised
Pre Seed - $125,000
August 26, 2021Lead Investor: PROTOCOL — by GETTYLAB, Y Combinator
Who are the founders of Promakhos Therapeutics
KC
Katerina Chatzi
Co-founder, Chief Executive Officer and President
JE
Jasper E. Neggers
Co-Founder, Chief Scientific Officer and Secretary
Investors
- Allston Venture Fund
- Asymmetry Ventures
- Pioneer Fund
- Y Combinator
- Metaplanet
- Harvard Venture Incubation Program
Market Focus
Promakhos Therapeutics primarily focuses on the biotechnology industry, specifically in developing therapies that enhance immune system function to control inflammation and promote healing.
Business Model
Develops and commercializes proprietary immunomodulatory therapies; revenue from product sales and partnerships.
See something that needs updating? Suggest edits to this profile.